The amplicon library preparation procedure was performed by the Illumina TruSeq DNA Sample Preparation Guide ... The sequencing results were compared with the BLAST algorithm’s GenBank database ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity.

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad ...

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN stock.

China imposed an import ban on Illumina’s gene sequencers in response to President Trump’s escalating tariffs and trade war ...

Illumina and next-gen sequencing (NGS) are synonymous. But to anyone paying attention, the company’s recent emphasis on multiomics has been hard to miss. Indeed, the company has launched both ...

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

We recently published a list of Jim Cramer’s Latest Lightning Round: 7 Stocks in Focus. In this article, we are going to take ...

Illumina, Inc., a global leader in next-generation sequencing and array-based technologies, announced a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with ...